Marisa Wexler, MS,  senior science writer—

Clinical Ink is partnering with a “leading biopharmaceutical organization” to monitor symptoms of people with Parkinson’s disease at home and clinical sites in the U.S. and Europe using the company’s technology. This will be part of a late-phase clinical development program, in which symptoms of Parkinson’s patients will…

Top-line results are expected next month from a Phase 2b clinical trial testing whether the investigational oral therapy mesdopetam can ease levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. IRLAB Therapeutics, the therapy’s original developer and sponsor of the trial, announced that the final participant…

Nitrase Therapeutics has partnered with HitGen in the search for novel therapies that suppress nitrases, a class of enzymes discovered by Nitrase. Nitrases are responsible for nitration, a type of biochemical modification of proteins that is linked to cellular stress and can change that protein’s structure, function, and…

The U.S. Food and Drug Administration (FDA) has put a hold on clinical trials of IkT-148009, an experimental oral therapy that Inhibikase Therapeutics is developing for Parkinson’s disease and other related and non-related conditions. The hold comes just a few months after Inhibikase started dosing Parkinson’s patients…

NeuroOne Medical Technologies announced it has successfully completed a feasibility study of its OneRF ablation system, which uses implanted electrodes to destroy targeted regions of the brain — and may help to control tremor in people with Parkinson’s disease — in animal models. The company is planning…

BioVie’s investigational oral therapy NE3107, taken in combination with standard levodopa, eases motor symptoms more substantially than levodopa alone in people with Parkinson’s disease, according to top-line results of a Phase 2 clinical trial. “NE3107 shows promise, and if the current findings are confirmed, it may represent one…

More than 30% of gut microbial species are found at abnormal numbers in Parkinson’s disease patients, according to a new analysis that assessed the gut microbiome in more detail than most prior studies. “We have shown that there is a widespread imbalance in the Parkinson’s [gut bacteria], creating an environment…

Pairing at-home healthcare visits with peer mentoring may help to prevent the strain of caregiving from worsening over time among people caring for homebound loved ones with advanced Parkinson’s disease, a study reported. “As the volume of family caregivers exponentially increases, peer mentoring — already a successful model in…

An experimental vaccine that stimulates immune responses against three regions of the alpha-synuclein protein — whose toxic clumps contribute to Parkinson’s disease and dementia with Lewy bodies (DLB) — is moving into late-stage preclinical research aimed at supporting future requests to test it in clinical trials. Called PV-1950R,…

New machine learning models based on walking patterns accurately distinguished between Parkinson’s patients and healthy people, and between different stages of the disease, a study showed. “We chose gait parameters as the key criteria because gait impairments appear early in Parkinson’s and get worse over time, and also because…